Tyra Biosciences, Inc.
Tyra Biosciences, Inc. (TYRA): 12 pipeline candidates · 4 upcoming catalysts · ~16 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.4 months
D/E 0.06 · 4% dilution
Lead: Phase 2
12 candidates
4 upcoming, next in ~12d
0 buys · 5 sells (180d)
A transparent, data-derived signal for Tyra Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$86.0M
Quarterly Burn
$32.6M
Runway
16.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| dabogratinib | Phase 2 |
| Dabogratinib TBD | Phase 2 |
| ifx-hu2.0 | Phase 1 |
| TYRA-200 | Phase 2 |
| TYRA-300 | Phase 1 |
| TYRA-300 0.125 mg/kg | Phase 2 |
| TYRA-300 0.25 mg/kg | Phase 2 |
| TYRA-300 0.375 mg/kg | Phase 2 |
| TYRA-300 0.50 mg/kg | Phase 2 |
| TYRA-300 Dose TBD | Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
160
Total value held
$2.20B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 12,198,625 | $467.2M |
| janus henderson group plc | 7,781,178 | $297.7M |
| fmr llc | 7,747,648 | $296.7M |
| farallon capital management llc | 3,580,818 | $137.1M |
| commodore capital lp | 2,475,000 | $94.8M |
| vanguard capital management llc | 2,251,940 | $86.2M |
| blackrock, inc. | 2,217,929 | $84.9M |
| bvf inc/il | 1,976,196 | $75.7M |
| caligan partners lp | 1,276,968 | $48.9M |
| state street corp | 1,216,078 | $46.6M |
Showing top 10 of 160 institutional holders of Tyra Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Tyra Biosciences, Inc.'s pipeline?
Tyra Biosciences, Inc. (TYRA) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tyra Biosciences, Inc.'s lead drug candidate?
Tyra Biosciences, Inc.'s most advanced tracked candidate is dabogratinib (Phase 2) for Low Grade Upper Tract Urothelial Carcinoma.
What is Tyra Biosciences, Inc.'s next catalyst?
Tyra Biosciences, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: tyra-300" — expected June 30, 2026.
What is Tyra Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tyra Biosciences, Inc. has approximately 16.4 months of cash runway.
What is Tyra Biosciences, Inc.'s market capitalization?
Tyra Biosciences, Inc.'s market capitalization is approximately $1.7B.
Get the full picture on Tyra Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.